Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type p53 (Ad-p53)

Nancy Yen, Constantin G. Ioannides, Kai Xu, Stephen G. Swisher, David D. Lawrence, Bonnie L. Kemp, Adel K. El-Naggar, Richard J. Cristiano, Bingliang Fang, Bonnie S. Glisson, Waun K. Hong, Fadlo R. Khuri, Jonathan M. Kurie, J. Jack Lee, Jin S. Lee, James A. Merritt, Tapas Mukhopadhyay, Jonathan C. Nesbitt, Dao Nguyen, Roman Perez-SolerKatherine M.W. Pisters, Joe B. Putnam, David S. Schrump, Dong M. Shin, Garrett L. Walsh, Jack A. Roth

Research output: Contribution to journalArticle

56 Scopus citations


The immune responses of 10 patients with advanced non-small cell lung cancer receiving monthly intratumoral injections of a recombinant adenovirus containing human wild-type p53 (Ad-p53) to adenovirus and transgene antigens were studied. The predominate cellular and humoral immune responses as measured by lymphocyte proliferation and neutralizing antibody (Ab) formation were to adenovirus serotype 5 vector antigens, with increased responses in posttreatment samples. Consistent alterations in posttreatment cellular and humoral immune responses to p53 epitopes were not observed, and cytotoxic Abs to human tung cancer cells were not generated. Patients in this study had evidence of an antitumoral effect of this treatment with prolonged tumor stability or regression; however, neither Abs to p53 protein nor increased lymphocyte proliferative responses to wild-type or mutant p53 peptides have been consistently detected.

Original languageEnglish (US)
Pages (from-to)530-536
Number of pages7
JournalCancer Gene Therapy
Issue number4
Publication statusPublished - Jan 1 2000
Externally publishedYes



  • Adenovirus vector
  • Anti-p53 antibodies
  • Lung cancer
  • Lymphocyte proliferation
  • p53

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Cancer Research

Cite this